Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Phone973-605-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.16 million
Profitability
Miscellaneous
Employees346
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Immunomedics (NASDAQ:IMMU) Frequently Asked Questions
What is Immunomedics' stock symbol?
Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."
How were Immunomedics' earnings last quarter?
Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.09. During the same quarter in the prior year, the firm posted ($0.68) earnings per share. View Immunomedics' Earnings History.
When is Immunomedics' next earnings date?
What price target have analysts set for IMMU?
9 brokerages have issued 1-year target prices for Immunomedics' shares. Their predictions range from $16.00 to $40.00. On average, they anticipate Immunomedics' stock price to reach $27.56 in the next twelve months. This suggests a possible upside of 71.3% from the stock's current price. View Analyst Price Targets for Immunomedics.
What is the consensus analysts' recommendation for Immunomedics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.
What are Wall Street analysts saying about Immunomedics stock?
Here are some recent quotes from research analysts about Immunomedics stock:
- 1. HC Wainwright analysts commented, "We remind investors that sacituzumab previously achieved a 31% 6.8-month median progression-free survival (mPFS) which, in our view, compares favorably to chemotherapy’s effect in this patient population (10-13% ORR and 3-4 month mPFS). Accordingly, we reiterate our Buy rating, while reducing our 12-month price target from $28 to $26 to account for the removal of the second- line HR+, HER2- mBC setting from our assumptions. IMMU-132 filing resubmission remains on track for early 4Q19." (8/8/2019)
- 2. According to Zacks Investment Research, "Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. " (7/16/2019)
Has Immunomedics been receiving favorable news coverage?
Press coverage about IMMU stock has trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Immunomedics earned a coverage optimism score of -3.6 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Immunomedics.
Are investors shorting Immunomedics?
Immunomedics saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 34,150,000 shares, a decline of 6.2% from the August 30th total of 36,400,000 shares. Based on an average daily volume of 2,200,000 shares, the days-to-cover ratio is currently 15.5 days. Approximately 19.7% of the shares of the company are sold short. View Immunomedics' Current Options Chain.
Who are some of Immunomedics' key competitors?
Some companies that are related to Immunomedics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), EXACT Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Immunomedics own?
Who are Immunomedics' key executives?
Immunomedics' management team includes the folowing people:
- Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)
- Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)
- Mr. Scott A. Canute MBA, Exec. Director (Age 58)
- Mr. Brendan Delaney, Chief Commercial Officer (Age 44)
- Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52)
Who are Immunomedics' major shareholders?
Immunomedics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.45%), Rhenman & Partners Asset Management AB (0.44%), CIBC Private Wealth Group LLC (0.05%), Brinker Capital Inc. (0.03%), Envestnet Asset Management Inc. (0.02%) and Strs Ohio (0.01%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc, Behzad Aghazadeh, Brian A Markison, Bryan Ball, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.
Which major investors are selling Immunomedics stock?
Which major investors are buying Immunomedics stock?
IMMU stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Fox Run Management L.L.C., Brinker Capital Inc., North Star Investment Management Corp., Envestnet Asset Management Inc. and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, Behzad Aghazadeh, Bryan Ball and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.
How do I buy shares of Immunomedics?
Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Immunomedics' stock price today?
One share of IMMU stock can currently be purchased for approximately $16.09.
How big of a company is Immunomedics?
Immunomedics has a market capitalization of $3.09 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,840,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 346 workers across the globe.View Additional Information About Immunomedics.
What is Immunomedics' official website?
How can I contact Immunomedics?
Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]
MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
